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Abstract
Pro-inflammatory prostaglandins are known to be first catabolized by NAD-dependent 15-hydroxyprostaglandin
dehydrogenase (15-PGDH) to inactive metabolites. This enzyme is under regulatory control by various inflammation-related
agents. Regulation of this enzyme was investigated in human promonocytic U937 cells. 15-PGDH activity was found to be
optimally induced by phorbol 12-myristate 13-acetate (PMA) at 10 nM after 24 h of treatment. The induction was blocked by
staurosporine or GF 109203X indicating that the induction was mediated by protein kinase C. The induction by PMA was
inhibited by the concurrent addition of dexamethasone. Nearly complete inhibition was observed at 50 nM. Other
glucocorticoids, such as hydrocortisone and corticosterone, but not sex hormones, were also inhibitory. Inhibition by
dexamethasone could be reversed by the concurrent addition of antagonist mifepristone (RU-486) indicating that the
inhibition was a receptor-mediated event. Either induction by PMA or inhibition by dexamethasone the 15-PGDH activity
correlated well with the enzyme protein expression as shown by the Western blot analysis. These results provide the first
evidence that prostaglandin catabolism is regulated by glucocorticoids at the therapeutic level. ß 2000 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Prostaglandins are a family of pro-in£ammatory
fatty acids derived from arachidonic acid through
the action of two isoforms of prostaglandin endoper-
oxide synthase or cyclooxygenase (COX) [1]. COX-1
appears to be responsible for the synthesis of pros-
taglandins necessary for housekeeping functions,
whereas COX-2 is induced to synthesize prostaglan-
dins in tissues in response to mitogens, growth
factors, tumor promoters and pro-in£ammatory cy-
tokines. Anti-in£ammatory steroids, such as dexa-
methasone, are able to inhibit the induction of
COX-2 as a plausible mechanism of action [2].
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Prostaglandins are rapidly metabolized and ex-
creted in the urine. The ¢rst step in the metabolism
of prostaglandins is catalyzed by NAD-dependent
15-hydroxyprostaglandin dehydrogenase (15-PGDH)
[3]. This enzyme is considered the key enzyme re-
sponsible for the biological inactivation of prosta-
glandins since the product 15-ketoprostaglandins
possess greatly reduced biological activities [4]. The
enzyme is ubiquitously present in mammalian tissues
[5]. However, only a few cell types, including HL-60
cells [6], HEL cells [7], and human monocytes [8^10],
have been identi¢ed to express the enzyme activity.
Regulation of the expression of this enzyme at the
cellular level has been studied in some instances.
Phorbol ester induces the synthesis of 15-PGDH in
HL-60 cells [6] and in HEL cells [7] possibly medi-
ated by protein kinase C activation. Dexamethasone
and other glucocorticoids at the micromolar level
stimulate the induction of 15-PGDH in HEL cells
and the induced enzyme can be inactivated by
PMA through a protein kinase C-mediated mecha-
nism [7]. 1,25-Dihydroxyvitamin D3 also induces 15-
PGDH in human neonatal monocytes [10]. Molecu-
lar basis of the induction by these di¡erent agents is
yet to be determined. However, the presence of a
number of potential regulatory elements, such as
Sp1, CRE, GRE, AP1 and AP2 in the promoter
region of the 15-PGDH gene may provide potential
binding sites for these agents to initiate gene tran-
scription [11].
In this study, we report that 15-PGDH is induced
by PMA in human promonocytic U937 cells and the
induction is inhibited by dexamethasone and other
glucocorticoids through a receptor-mediated mecha-
nism. This is the ¢rst report documenting that dex-
amethasone is able to inhibit prostaglandin catabo-
lism through inhibition of catabolic enzyme
induction at subnanomolar concentrations.
2. Materials and methods
2.1. Materials
Phorbol 12-myristate 13-acetate (PMA), 4K-phor-
bol 12,13-didecanoate (PDD), NAD, K-ketogluta-
rate, dithiothreitol (DTT), staurosporine, bovine liv-
er glutamate dehydrogenase (40 U/mg), RPMI 1640,
penicillin, streptomycin, dexamethasone (DEX), mi-
fepristone (RU-486), hydrocortisone, corticosterone,
estradiol, progesterone, and phenylmethylsulfonyl
£uoride (PMSF) were obtained from Sigma. GF
109203X was purchased from Alexis. PGE2 was sup-
plied by Cayman. ECL plus Western Blotting De-
tection System RPN 2132 was from Amersham.
Rabbit antiserum against human 15-PGDH was gen-
erated as described previously [12]. 15(S)-[15-
3H]PGE2 was prepared according to a previously
published procedure [13]. Human promonocytic
U937 cells were obtained from the American Type
Culture Collection. Other reagents were obtained
from the best commercial sources.
2.2. Cell culture
U937 cells were cultured in RPMI 1640 medium
containing 10% fetal calf serum, 100 U penicillin/ml
and 100 Wg streptomycin/ml at 37‡C in a humidi¢ed
atmosphere of 5% CO2. The cells were plated in 6-
well plates (2 ml/well) at about 5U105 cells/ml in
duplicate and grown overnight before treatment.
2.3. Treatment of U937 cells
After U937 cells were grown overnight, cells in
each well received treatment with phorbol esters,
dexamethasone, protein kinase C inhibitors or other
steroids either alone or in di¡erent combinations as
described in the ¢gure legends.
2.4. Preparation of U937 cell homogenate
U937 cells from the above culture were spun down
at maximal speed in a microfuge for 2 min and
washed once with saline. About 1U10 6 cells were
suspended in 1 ml of 0.05 M Tris^HCl bu¡er, pH 7.5
containing 1 mM DTT and sonicated in an ice bath
for 3U10 s by an ultrasonic sonicator set at 4. The
crude homogenate was used as an enzyme prepara-
tion.
2.5. Enzyme assay
15-PGDH was routinely assayed by measuring the
transfer of 3H from 15(S)-[15-3H ]PGE2 to glutamate
by coupling 15-PGDH with glutamate dehydrogen-
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ase as described previously [13]. Brie£y, the reaction
mixture contained NH4Cl (5 Wmol), K-oxo-glutarate
(1 Wmol), NAD (1 Wmol), 15(S)-[15-3H ]PGE2 (1
nmol, 30 000 cpm), glutamate dehydrogenase (100
Wg), DTT (1 Wmol) and 15-PGDH enzyme prepara-
tion in a ¢nal volume of 1 ml of 0.05-M Tris^HCl,
pH 7.5. The reaction was allowed to continue for 10
min at 37‡C, and was terminated by the addition of
0.3 ml of 10% aqueous charcoal suspension. After
incubation for 5 min, the mixture was centrifuged
at 2000Ug for 5 min. The radioactivity in the super-
natant was determined by liquid scintillation count-
ing. Calculation of the amount of PGE2 oxidized was
based on the assumption that no kinetic isotope ef-
fect was involved in the oxidation of the 15(S)-hy-
droxyl group of 15(S)-[15-3H]PGE2 as substrate. En-
zyme activity of U937 sample was always assayed in
duplicate.
2.6. SDS^PAGE and immunoblot analysis
U937 cells either treated or incubated with di¡er-
ent stimuli were homogenated in phosphate-bu¡ered
saline containing 1 mM PMSF by sonication in an
ice bath for 3U10 s. About 150 Wg of cellular extract
was resolved by SDS^PAGE (12% gel) according to
the method of Laemmli [14]. Electrophoretic transfer
of proteins from the gel to PVDF membrane was
performed according to the method of Towbin et
al. [15]. The membrane was blocked with 5% non-
fat dry milk in 0.03 M Tris^HCl, pH 7.4 containing
120 mM NaCl and 0.05% Tween-20 (TBST) followed
by incubation with a rabbit antiserum against the
human placental 15-PGDH (1:2000 dilution in
TBST with 5% non-fat milk) at room temperature
for 2 h. After washing with TBST three times, the
membrane was incubated with Protein A-HRP
(1:5000 dilution in TBST with 5% non-fat milk) for
1 h at room temperature. The immunoreactive bands
were detected with ECL Plus Western Blotting De-
tection System. The intensity of the immunoreactive
bands was determined by NIH 1.61 image.
2.7. Statistical analysis
Each enzyme sample was performed in duplicate.
The data were expressed as the mean þ S.E. Statisti-
cal signi¢cance was assessed by Student’s t-test using
a P value of 6 0.05. Each ¢gure is a representative of
2^4 replications.
3. Results
Human promonocytic U937 cells were found to
express 15-PGDH activity following treatment with
PMA. The time course of 15-PGDH induction by
PMA is shown in Fig. 1. Maximum induction was
observed at 24^36 h following the addition of PMA
as shown by the activity assay (Fig. 1a) and by im-
munoblot analysis (Fig. 1b). The e¡ect of increasing
concentrations of PMA on 15-PGDH induction is
shown in Fig. 2. Maximal stimulation of 15-PGDH
activity by PMA was observed at 10 nM as shown in
Fig. 2. Higher concentrations of PMA were not as
e¡ective. PDD, an inactive phorbol ester, was shown
Fig. 1. The time course of 15-PGDH induction by PMA. U937
cells were treated with 10 nM of PMA for the indicated length
of time. Cells were then washed and sonicated for the determi-
nation of 15-PGDH activity (a) and 15-PGDH immunoreactivi-
ty (b) as described in Section 2. Puri¢ed recombinant 15-
PGDH (S) detected as a 29-kDa protein was included in the
immunoblot. The higher molecular weight band was considered
a non-speci¢c protein detected by the antibodies.
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to be unable to stimulate 15-PGDH activity at the
concentrations tested. Stimulation of 15-PGDH ac-
tivity by PMA was found to be inhibited by the
addition of the protein kinase C inhibitors, stauro-
sporine and GF 109203X [16,17]. Fig. 3 shows the
e¡ects of increasing concentrations of staurosporine
or GF 109203X on PMA-induced stimulation of 15-
PGDH activity. Almost total inhibition by stauro-
sporine was observed at 100 nM, whereas about
75% inhibition by GF 109203X was seen at 1 WM.
Concurrent addition of dexamethasone with 10
nM PMA inhibited PMA-induced stimulation of
15-PGDH activity in a concentration-dependent
manner as shown in Fig. 4. Approximately 75% in-
hibition was seen at 10 nM. More than 90% inhibi-
tion was observed at 100 nM. The induction of 15-
PGDH activity by PMA and the inhibition of dex-
amethasone were accompanied by the expression of
enzyme protein as shown in Fig. 5. Western blot
indicated that expression of enzyme protein was
stimulated by PMA as revealed by the appearance
Fig. 3. E¡ect of staurosporine and GF 109203X on the induc-
tion of 15-PGDH activity by PMA. (a) U937 cells were treated
either with staurosporine (a) or with 10 nM PMA plus stauro-
sporine (b) at the indicated concentrations for 24 h. (b) U937
cells were treated either with GF 109203X (a) or with 10 nM
PMA plus GF 109203X (b) at the indicated concentrations for
24 h. Cells were washed and sonicated for determination of 15-
PGDH activity as described in Section 2.
Fig. 2. E¡ects of PMA and PDD on 15-PGDH activity. U937
cells were treated with the indicated concentrations of PMA (b)
or PDD (a) for 24 h. Cells were washed and sonicated for de-
termination of 15-PGDH activity as described in Section 2.
Table 1
The e¡ect of steroids on the induction of 15-PGDH activity by
PMA in U937 cells
Activity (pmol/min/
106 cells)
Inhibition
(%)
Vehicle 5.9 þ 1.3
PMA 52.5 þ 2.8 0
PMA+dexamethasone 10.1 þ 0.9 90.9
PMA+hydrocortisone 25.1 þ 3.0 58.7
PMA+corticosterone 23.6 þ 4.1 62.1
PMA+estradiol 47.6 þ 3.5 10.5
PMA+testosterone 46.6 þ 3.1 12.1
PMA+progesterone 46.2 þ 2.6 13.5
PMA+mifepristone 47.3 þ 3.9 11.1
U937 cells were treated either with vehicle, PMA (10 nM) alone
or PMA plus various steroids (1 WM each) for 24 h. Cells were
washed and sonicated for determination of 15-PGDH activity
as described in Section 2. % inhibition was calculated after sub-
straction of basal activity.
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of a 29-kDa protein which is the subunit size of 15-
PGDH. The expression of 15-PGDH was nearly
abolished by the addition of 10 nM dexamethasone
and was completely blocked by the addition of 100
nM dexamethasone. Inhibition of PMA-mediated in-
duction of 15-PGDH by dexamethasone was also
observed with other glucocorticoids as shown in Ta-
ble 1. More than 50% of the 15-PGDH activity in-
duced by PMA was found to be inhibited by hydro-
cortisone and corticosterone at 1 WM. Other sex
hormones and steroid receptor antagonist, mifepri-
stone [18] showed much less inhibitory activity.
To examine if inhibition by dexamethasone is a
receptor-mediated event, steroid receptor antagonist,
mifepristone (RU-486), in increasing concentrations
was added along with 10 nM dexamethasone during
induction of 15-PGDH activity by PMA. Fig. 6
shows that mifepristone itself had little e¡ect on
PMA-induced 15-PGDH activity. However, dexa-
methasone-mediated inhibition of PMA-induced en-
zyme activity was reversed by mifepristone in a con-
centration-dependent manner. Mifepristone at 1 WM
recovered most of the enzyme activity. Again, mife-
pristone did not a¡ect the induction of the 29-kDa
protein by PMA, but was able to antagonize the
e¡ect of dexamethasone since the expression of the
29-kDa protein still persisted when both dexametha-
sone and mifepristone were added as shown in Fig.
5. It appears that the induction of 15-PGDH activity
coincided with the expression of the 29-kDa protein.
4. Discussion
Human promonocytic U937 cells have been shown
Fig. 5. Western blot analysis of 15-PGDH from U937 cells
treated with PMA, dexamethasone, mifepristone (RU-486) or
any combinations of the three di¡erent compounds. U937 cells
were treated with vehicle (lane 1), PMA alone (10 nM, lane 2),
dexamethasone alone (100 nM, lane 3), PMA (10 nM) plus dex-
amethasone (10 nM, lane 4), PMA (10 nM) plus dexametha-
sone (100 nM, lane 5), PMA (10 nM) plus dexamethasone (100
nM) and RU-486 (1 WM, lane 6), PMA (10 nM) plus RU-486
(1 WM, lane 7), or RU-486 alone (1 WM, lane 8) for 24 h. Cells
were lysed and 150 Wg protein was applied to each lane for
SDS^PAGE and immunoblot analysis as described in Section 2.
Puri¢ed Recombinant human 15-PGDH (S, lane 9) detected as
a 29-kDa protein was run at the same time. The higher molecu-
lar band was considered a non-speci¢c protein detected by the
antibodies.
Fig. 4. E¡ect of dexamethasone on the induction of 15-PGDH
activity by PMA. U937 cells were treated either with dexameth-
asone (a) or with 10 nM PMA plus dexamethasone (b) at the
indicated concentrations for 24 h. Cells were washed and soni-
cated for determination of 15-PGDH activity as described in
Section 2.
Fig. 6. Inhibition of PMA-induced 15-PGDH activity by dexa-
methasone is reversed by mifepristone. U937 cells were treated
with 10 nM PMA plus the indicated concentrations of mifepri-
stone (a) or 10 nM PMA plus 100 nM dexamethasone and the
indicated concentrations of mifepristone (b) for 24 h. Cells
were washed and sonicated for determination of 15-PGDH ac-
tivity as described in Section 2.
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to exhibit prostaglandin biosynthetic activity follow-
ing exposure to PMA [19]. The increase in biosyn-
thetic activity was attributed to the induction of cy-
clooxygenase expression. Similar induction of
prostaglandin biosynthetic activity by PMA was
also observed with other leukemia cell lines, such
as THP-1 [20] and HL-60 [21] cells. In addition to
the induction of cyclooxygenase activity, PMA also
stimulates the expression of 15-PGDH in HL-60 cells
[6]. We examined, in this study, if PMA also induced
the expression of 15-PGDH in addition to the ex-
pression of cyclooxygenase in U937 cells. The results
indicate that the catabolic enzyme, 15-PGDH, was
also induced by PMA. The expression of 15-PGDH
activity in human monocytes was ¢rst suggested by
Serhan’s group who found that lipoxin A4 (LXA4)
was rapidly metabolized to 15-oxo-LXA4, 13,14-di-
hydro-15-oxo-LXA4 and 13,14-dihydro-LXA4 in ad-
herent human monocytes [8]. The ¢rst step in the
metabolism of LXA4 is catalyzed by 15-PGDH
which metabolizes hydroxy fatty acids as well as
prostaglandins [22,23]. Recently, Dichaud et al. [10]
reported that 15-PGDH-related mRNA was consti-
tutively expressed in adult human monocytes and 15-
PGDH activity could be induced by 1,25-dihydroxy-
vitamin D3 in human neonatal monocytes. Whether
15-PGDH can be induced by PMA in these mono-
cytes was not explored. Our ¢nding in U937 cells
suggests that 15-PGDH may be also induced by
PMA in human monocytes.
The concentrations of PMA needed to induce 15-
PGDH activity in U937 cells were comparable to
those used in the induction of 15-PGDH in HL-60
cells [6]. PMA at 10 nM appeared to be optimal.
Higher concentrations were found to be less e¡ective.
Studies in HL-60 cells [6] and HEL cells [7] indicate
that higher concentrations of PMA may cause inac-
tivation of 15-PGDH through PMA-mediated pro-
tein kinase C catalyzed phosphorylation of the en-
zyme. Whether this is true in U937 cells remains to
be determined. The induction of 15-PGDH expres-
sion by PMA appears to be mediated by the activa-
tion of protein kinase C. This is supported by several
lines of evidence. Firstly, PMA, a potent activator of
protein kinase C, induced a concentration-dependent
induction of 15-PGDH activity and enzyme protein,
whereas inactive phorbol ester, PDD, did not show
enzyme induction at any concentration tested. Sec-
ondly, two di¡erent types of protein kinase C inhib-
itors, staurosporine and GF 109203X, were able to
inhibit PMA-induced expression of 15-PGDH activ-
ity. Thirdly, the induction of 15-PGDH by PMA is
consistent with the fact that AP-1, AP-2 and CRE
regulatory sequences, which are known to be in-
volved in PMA-mediated protein kinase C-induced
responses in other genes, are found in the 5P-£anking
region of 15-PGDH gene [11].
The induction of 15-PGDH in U937 cells by PMA
was found to be inhibited by dexamethasone at
nanomolar concentrations. Inhibition by dexametha-
sone is shared by other glucocorticoids, but not sig-
ni¢cantly by sex hormones, indicating that inhibition
of PMA-induced expression of 15-PGDH is a general
property of anti-in£ammatory glucocorticoids. Lack
of e¡ect by sex hormones may be also due to the
absence of expression of the cognate receptors for
these hormones in U937 cells. Glucocorticoids have
also been demonstrated to block the induction of
prostaglandin synthetic enzyme, cyclooxygenase-2
at nanomolar concentrations [2]. It was thought to
be a mode of action of anti-in£ammatory glucocorti-
coids. The inhibitory e¡ect of dexamethasone on
PMA-induced expression of 15-PGDH appeared to
be a receptor-mediated event since the inhibition
could be reversed by the presence of steroid receptor
antagonist, mifepristone. However, the reversal was
found to be incomplete. This could be due to the
partial agonist activity of mifepristone since mifepri-
stone itself showed some inhibition of PMA-induced
15-PGDH activity (Table 1). Partial agonist activity
of mifepristone has been observed in other systems
[24,25]. Repression of 15-PGDH expression by dexa-
methasone is in direct contrast to a previous report
in which glucocorticoids were found to induce 15-
PGDH in HEL cells [7]. However, the concentrations
needed to induce 15-PGDH in HEL cells were at the
submicromolar range of dexamethasone. Further-
more, progesterone was also found to be a potent
inducer of 15-PGDH in HEL cells. This study shows
that progesterone did not signi¢cantly inhibit
PMA-induced expression of 15-PGDH activity in
U937 cells. Micromolar concentrations of dexameth-
asone also did not induce expression of 15-PGDH
activity in U937 cells. Therefore, it appears that
steroid e¡ect on 15-PGDH gene expression is cell
type speci¢c.
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The mechanism(s) through which dexamethasone
represses PMA-induced expression of 15-PGDH is
not known. It is generally believed that dexametha-
sone acts by binding to the cytosolic glucocorticoid
receptor which then translocates into the nucleus and
engages in regulation of gene expression [26,27].
Most of the functions carried out by glucocorticoid
receptor are at the level of transcriptional control,
although some of which are post-transcriptional
[28,29]. Transcriptional repression by the glucocorti-
coid receptor may be based on protein^protein inter-
action between the receptor and other transcriptional
factors without the recruitment for DNA binding by
the receptor [30]. Dexamethasone has been shown to
repress the expression of cyclooxygenase-2 induced
by PMA in part through CRE [31]. Although the
mechanism by which dexamethasone elicits events
that antagonize the activation of CRE is not clear,
one plausible mechanism is that ligand^receptor
complex interferes with CREB binding to its cis-act-
ing element. A report indicating an interaction be-
tween CREB and the glucocorticoid receptor in hu-
man peripheral blood mononuclear cells has
appeared [32]. The presence of CRE, AP-1 and AP-
2, which are known to be involved in PMA-induced
responses in other genes, in the 5P-£anking region of
15-PGDH gene indicates that dexamethasone may
suppress the expression of 15-PGDH through inhib-
itory interaction with these potential regulatory ele-
ments.
Our ¢nding that inhibition of PMA-induced ex-
pression of 15-PGDH by dexamethasone at the ther-
apeutic level is a novel one. If prostaglandins are
pro-in£ammatory and dexamethasone is anti-in£am-
matory, one would expect that dexamethasone
should enhance prostaglandin catabolism by stimu-
lating the activity of 15-PGDH to facilitate removal
of prostaglandins. In contrast, the inhibition of 15-
PGDH expression, a previously unreported e¡ect of
dexamethasone, would appear to be a paradoxical
e¡ect of this anti-in£ammatory drug. Similar para-
doxical situation was found in the induction of cyclo-
oxygenase-1 by dexamethasone and stem cell factor
in mast cells [33]. However, recent evidence indicates
that 15-PGDH may also regulate the action of en-
dogenous anti-in£ammatory eicosanoids, such as lip-
oxins and aspirin-triggered lipoxins (ATL) by oxidiz-
ing and inactivating these eicosanoids [8,34]. Several
studies using stable lipoxin analogs and ATL lipoxin
analogs, which resist rapid inactivation by 15-
PGDH, showed that their anti-in£ammatory actions
were prolonged in vivo [34^36]. In view of these re-
cent results and our ¢ndings, it appears that the anti-
in£ammatory action of dexamethasone may do so by
prolonging the action(s) and in vivo biohalf-life of
anti-in£ammatory eicosanoids, such as lipoxins and
ATL.
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